BusinessCapricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular DystrophyBy Nasdaq OMXApr 30, 2018, 11:01 AM UTC
BusinessCapricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease ModelBy Nasdaq OMXApr 19, 2018, 11:00 AM UTC
BusinessCapricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy TherapyBy Nasdaq OMXFeb 5, 2018, 4:11 PM UTC
